TY - JOUR
T1 - Crystal structure of glycinamide ribonucleotide transformylase from Escherichia coli at 3·0 Å resolution. A target enzyme for chemotherapy
AU - Chen, Ping
AU - Schulze-Gahmen, Ursula
AU - Stura, Enrico A.
AU - Inglese, James
AU - Johnson, Dana L.
AU - Marolewski, Ariane
AU - Benkovic, Stephen J.
AU - Wilson, Ian A.
N1 - Funding Information:
We thank Dr W. Furey for help with the map averaging, M. Pique for generating Figure 3(a), and Dr R. Stanfield and D. Fremont for discussions. This is publication no. 7349.MB from the Scripps Research Institute. Supported in part by N.I.H. grant GM 24129 (S.J.B). The
PY - 1992/9/5
Y1 - 1992/9/5
N2 - The atomic structure of glycinamide ribonucleotide transformylase, an essential enzyme in purine biosynthesis, has been determined at 3·0 Å resolution. The last three C-terminal residues and a sequence stretch of 18 residues (residues 113 to 130) are not visible in the electron density map. The enzyme forms a dimer in the crystal structure. Each monomer is divided into two domains, which are connected by a central mainly parallel seven-stranded β-sheet. The N-terminal domain contains a Rossmann type mononucleotide fold with a phosphate ion bound to the C-terminal end of the first β-strand. A long narrow cleft stretches from the phosphate to a conserved aspartic acid, Aspl44, which has been suggested as an active-site residue. The cleft is lined by a cluster of residues, which are conserved between bacterial, yeast, avian and human enzymes, and likely represents the binding pocket and active site of the enzyme. GAR Tfase binds a reduced folate cofactor and glycinamide ribonucleotide for the catalysis of one of the initial steps in purine biosynthesis. Folate analogs and multi-substrate inhibitors of the enzyme have antineoplastic effects and the structure determination of the unliganded enzyme and enzyme-inhibitor complexes will aid the development of anti-cancer drugs.
AB - The atomic structure of glycinamide ribonucleotide transformylase, an essential enzyme in purine biosynthesis, has been determined at 3·0 Å resolution. The last three C-terminal residues and a sequence stretch of 18 residues (residues 113 to 130) are not visible in the electron density map. The enzyme forms a dimer in the crystal structure. Each monomer is divided into two domains, which are connected by a central mainly parallel seven-stranded β-sheet. The N-terminal domain contains a Rossmann type mononucleotide fold with a phosphate ion bound to the C-terminal end of the first β-strand. A long narrow cleft stretches from the phosphate to a conserved aspartic acid, Aspl44, which has been suggested as an active-site residue. The cleft is lined by a cluster of residues, which are conserved between bacterial, yeast, avian and human enzymes, and likely represents the binding pocket and active site of the enzyme. GAR Tfase binds a reduced folate cofactor and glycinamide ribonucleotide for the catalysis of one of the initial steps in purine biosynthesis. Folate analogs and multi-substrate inhibitors of the enzyme have antineoplastic effects and the structure determination of the unliganded enzyme and enzyme-inhibitor complexes will aid the development of anti-cancer drugs.
UR - http://www.scopus.com/inward/record.url?scp=0026758035&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026758035&partnerID=8YFLogxK
U2 - 10.1016/0022-2836(92)90698-J
DO - 10.1016/0022-2836(92)90698-J
M3 - Article
C2 - 1522592
AN - SCOPUS:0026758035
SN - 0022-2836
VL - 227
SP - 283
EP - 292
JO - Journal of Molecular Biology
JF - Journal of Molecular Biology
IS - 1
ER -